CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
1,071.00
-99.00 (-8.46%)
May 28, 2025, 3:30 PM JST
112.08%
Market Cap 20.47B
Revenue (ttm) n/a
Net Income (ttm) -1.49B
Shares Out 19.11M
EPS (ttm) -79.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 818,000
Average Volume 544,240
Open 1,167.00
Previous Close 1,170.00
Day's Range 1,064.00 - 1,174.00
52-Week Range 432.00 - 1,512.00
Beta -1.30
RSI 47.99
Earnings Date May 13, 2025

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 11
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.